PathWhiz ID | Pathway | Meta Data |
---|---|---|
PW146619View Pathway |
drug action
Pramiracetam Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 18:38 Last Updated: October 07, 2023 at 18:38 |
PW145355View Pathway |
drug action
Pramlintide Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 15:38 Last Updated: October 07, 2023 at 15:38 |
PW146104View Pathway |
drug action
Pramocaine Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 17:25 Last Updated: October 07, 2023 at 17:25 |
PW145496View Pathway |
drug action
Prasterone Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 15:56 Last Updated: October 07, 2023 at 15:56 |
PW146964View Pathway |
drug action
Prasterone enantate Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 19:27 Last Updated: October 07, 2023 at 19:27 |
PW122427View Pathway |
drug action
Prasugrel ActionHomo sapiens
|
Creator: Eponine Oler Created On: April 08, 2019 at 15:30 Last Updated: April 08, 2019 at 15:30 |
PW128062View Pathway |
drug action
Prasugrel Action PathwayHomo sapiens
Prasugrel is a platelet inhibitor acting to reduce thrombotic events, its brand name is Effient or Efient. It is a prodrug meaning that once administered orally it goes through first-pass metabolism in the liver to be metabolized to its active form. Once in its active form it travels to the bloodstream and acts on the P2Y12 receptor in platelets. By irreversibly binding to the P2Y12 receptors it impairs ADP mediated activation of glycoprotein GPIIb/IIIa complex. Due to the anticoagulant and antiplatelet activity, it is recommended to avoid herbs and supplements with similar activity such as garlic, ginger, bilberry, danshen, piracetam and ginkgo biloba.
|
Creator: Selena Created On: July 12, 2023 at 13:06 Last Updated: July 12, 2023 at 13:06 |
PW145678View Pathway |
drug action
Prasugrel Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 16:22 Last Updated: October 07, 2023 at 16:22 |
PW176400View Pathway |
Prasugrel Predicted Metabolism PathwayHomo sapiens
Metabolites of Prasugrel are predicted with biotransformer.
|
Creator: Omolola Created On: December 07, 2023 at 16:50 Last Updated: December 07, 2023 at 16:50 |
PW000133View Pathway |
drug action
Pravastatin Action PathwayHomo sapiens
Pravastatin inhibits cholesterol synthesis via the mevalonate pathway by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase is the enzyme responsible for the conversion of HMG-CoA to mevalonic acid, the rate-limiting step of cholesterol synthesis by this pathway. Pravastatin bears a chemical resemblance to the reduced HMG-CoA reaction intermediate that is formed during catalysis. Structure-activity relationship studies have demonsotrated that statins bind to HMG-CoA reductase at the same site as the reduced reaction intermediate and are held in place by similar chemical interactions. Cholesterol biosynthesis accounts for approximately 80% of cholesterol in the body; thus, inhibiting this process can significantly lower cholesterol levels. Pravstatin was derived from the microbial transformation of mevastatin, which is a natural compound produced by Penicillium citinium and the first statin ever studied. Unlike lovastatin and simvastatin, pravastatin is relatively hydrophilic and does not require hydrolysis for activation. Increased hydrophilicity accounts for its decreased penetration of lipophilic peripheral cells, increased selectivity for hepatic tissues and decreased side effects relative to simvastatin and lovastatin.
|
Creator: WishartLab Created On: August 04, 2013 at 21:09 Last Updated: August 04, 2013 at 21:09 |